|
|
PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study
Rene-Olivier Casasnovas
,
Reda Bouabdallah
,
Pauline Brice
,
Julien Lazarovici
,
Hervé Ghesquieres
et al.
Lancet Oncology, 2019
Journal articles
hal-01996114v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Mutational landscape of gray zone lymphoma
Clémentine Sarkozy
,
Stacy Hung
,
Elizabeth Chavez
,
Gerben Duns
,
Katsuyoshi Takata
et al.
Journal articles
hal-03257279v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
CD19 CAR T-Cell Therapy in Patients with Relapse/Refractory DLBCL: Retrospective Analysis of the Eligibility Criteria
Jerome Paillassa
,
Roberta Di Blasi
,
Sylvie Chevret
,
Sophie Bernard
,
Michael Darmon
et al.
Journal articles
hal-03605011v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
Catherine Thieblemont
,
Hervé Tilly
,
Maria Gomes Da Silva
,
Rene-Olivier Casasnovas
,
Christophe Fruchart
et al.
Journal articles
hal-01609346v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Bendamustine-EAM versus R-BEAM after high-dose cytarabine-based induction in newly diagnosed patients with mantle cell lymphoma, a LYSA retrospective study
Domitille Costes-Tertrais
,
Thomas Hueso
,
Thomas Gastinne
,
Catherine Thieblemont
,
Lucie Oberic
et al.
Journal articles
hal-03608256v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|